91 results about "Schistosomiases" patented technology

The invention relates to an application of a 2-aryl substituted pyrrole compound in a drug for killing bulinus, and belongs to the technical field of schistosomiasis control. The invention particularly provides a chemical structure and preparation method of the 2-aryl substituted pyrrole compound. A molluscicide is prepared with the 2-aryl substituted pyrrole compound as the active ingredient. Themolluscicide has a form of suspension agent, emulsion or microemulsion, and is applied to kill bulinus. When the 2-aryl substituted pyrrole compound is used as the active ingredient of the molluscicide, the application amount for soaking killing is 0.5 mg / L-10.00 mg / L, and the soaking killing time is 24 h-72 h. Experiments prove that the 2-aryl substituted pyrrole compound has the killing activity against bulinus, has the toxicity to aquatic organisms lower than that of conventional snail-killing drug niclosamide, and can be made into the molluscicide applied in the field of schistosomiasis control.

The invention relates to the field of genetic engineering antibody, and builds schistosoma japonicum immature egg soluble antigen (SIEA) single-chain antibody library for the first time. By screening the SIEA single-chain antibody library through an immuno-affinity screening technique, a specific single-chain antibody aiming at anti-schistosomiasis-japonica effective natural molecular vaccine SIEA26-28kDa is obtained. The obtainment of the specific single-chain antibody provides a foundation for treating schistosomiasis japonica, utilizing the specific single-chain antibody as a probe to screen schistosoma japonicum cDNA libraries and obtaining a corresponding gene sequence aiming at anti-schistosomiasis-japonica effective vaccine molecules more conveniently and rapidly.

The invention discloses a single-chain antibody of an anti-schistosome monoclonal NP11-4 as well as a preparation method and application thereof, and relates to the field of gene engineering and the field of therapeutic drugs against schistosomiasis. The invention is to use a monoclonal antibody NP11-4 located at adult membrane, cercaria memberane, schistosomulum membrane, egg shell and miracidium in egg of Schistosoma japonicum, extract total RNA of hybridoma cells through a gene engineering technology, adopt RT-PCR for proliferation of genes VH and VL, and use overlap-extension PCR to connect the genes VH and VL into a single-chain antibody gene in the form of VH<-linker-VL, which is subsequently connected with a pBAD / gIIIA carrier and cloned into Top10F'of Escherichia Coli to induce a soluble expression of the target gene. The zone from amino acid No.1 to No. 122 of the expressed single-chain antibody of the anti-schistosome monoclonal NP11-4 is a heavy chain gene repertoire of the single-chain antibody (VH), and the zone from the amino acid No.141 to No.254 is a light chain gene repertoire (VL) of the single-chain antibody, wherein the linker between the heavy and light chain gene repertoires consists of 18 amino acids including repeated glycines and serines, and the single-chain antibody has 254 amino acids in full length.

Anti-Schistosoma japonicum thioredoxin glutathione reductase Sj ? The invention relates to a TGR single-region antibody and a preparation method thereof, which belong to the technical fields of molecular biology, immunology and pharmacy of biotechnology. The present invention provides an anti- Sj ? Recombinant phage display library of single-region antibody of TGR protein, anti- Sj ? Single region antibody of TGR protein and preparation method thereof, described anti Sj ? TGR single domain antibody can be combined with Sj ? TGR protein specifically binds, and / or has inhibitory Sj The TGR enzyme activity can be used to prepare new drugs for treating schistosomiasis or targeted carriers of therapeutic drugs. The invention lays a good foundation for the development of new schistosomiasis therapeutic drugs and new treatment methods, and has important significance for controlling the prevalence of schistosomiasis.

This invention relates to compositions for the prevention and treatment of schistosomiais comprising a polyunsaturated fatty acid and a therapeutic agent. The invention further relates to methods for the prevention and treatment of schistosomiasis, methods to confer resistance to schistosomiasis and methods to prevent re-occurrence of schistosomiasis comprising administration of a polyunsaturated fatty acid and a therapeutic agent.

The invention discloses the application of a serum protein marker group of isopentenyl cysteine ​​oxidase and apolipoprotein in the preparation and identification of classical advanced schistosomiasis and newly developed advanced schistosomiasis detection kits, using iTRAQ combined with MRM technology , to identify and verify the serum proteins in the serum of classic late blood patients, newly developed late blood patients and normal people. 2-3 times of those in the newly developed late blood group; in the newly developed late blood group, the expression level of apolipoprotein was 2 times that of the classic late blood group. The invention also discloses a detection kit for distinguishing classic advanced schistosomiasis from newly developed advanced schistosomiasis, which comprises isopentenyl cysteine ​​oxidase polyclonal antibody, apolipoprotein polyclonal antibody, sample loading buffer and ELISA 96-well plate. The kit of the invention can accurately distinguish classic type and newly developed advanced schistosomiasis, and has great market prospect.